Ocugen Inc (OCGN)

$2.04 -0.20 (-8.93%)
Market Cap 750.88M
Revenue (ttm) 4.41M
Net Income (ttm) -67.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,538.55%
Debt to Equity Ratio 8.05
Volume 25,070,000
Avg Vol 7,967,392
Day's Range N/A - N/A
Shares Out 327.90M
Stochastic %K 35%
Beta 2.75
Analysts Strong Sell
Price Target $10.57

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 328 4701
Address:
11 Great Valley Parkway, Malvern, United States
Martinsucks
Martinsucks Mar. 21 at 10:37 PM
$OCGN horse manure stock.
0 · Reply
James94E
James94E Mar. 21 at 10:13 PM
$OCGN is it Monday yet?.................. ........... What about now?
0 · Reply
simbha
simbha Mar. 21 at 10:05 PM
$OCGN Last 4 weeks markets are at peak and war uncertainty made big players to swing huge on simple expected news and then cash out. I think similar big investors (warrants) played similar game. CEO is happy and so did warrant player. Meanwhile big sharks and MM cashed out on options and added to their long term. Retailers we were as usual emotional excited as well as disappointed. Usual compromise that we will prosper on lon term @$20. Good luck longs..
0 · Reply
Merlintrader
Merlintrader Mar. 21 at 8:43 PM
$OCGN https://www.merlintrader.com/biotech-trading-without-the-fairy-tales-risks-catalysts-and-reality/
0 · Reply
Tradefun1979
Tradefun1979 Mar. 21 at 8:29 PM
$OCGN Not again, this time please!6 years a long time to do a business correctly. Promoters should pay attention and keep this floating. Some are really frustrated like me and very reasonably. But hope will persist for the incoming pr.
0 · Reply
elronjr
elronjr Mar. 21 at 8:00 PM
$OCGN $BTAI $HUMA $BMEA $NOTE I took a beating this week. Note is as per usual garbage and a lost cause at this point. Really hoping earnings reports this week for $BTAI $HUMA $BMEA pull through and actually save me. This is an absolute shitshow. Humacyte probably has the dumbest people running the company. I’m hoping they have something up their sleeve this ER to have that damn stock go above 1-1.5$
1 · Reply
luminouslumens
luminouslumens Mar. 21 at 7:54 PM
$ASST $VTIX $OCGN $IKT $LPTH Some block flow leaders to watch next week!!
0 · Reply
DookieDungaroos
DookieDungaroos Mar. 21 at 4:51 PM
$OCGN
2 · Reply
jacksparo
jacksparo Mar. 21 at 4:01 PM
$SLS Automatic shelf offering but remember everyone here most likely still betting big on what might happen post Regal results announced. The rumors, the exaggeration, the epic optimization all part of some people way of expressing but I am personally go by what the numbers will tell… I will share my update and my plan in a full detailed email this weekend with realistic predictions and remember risk always going to be part of the Biotech Game! $IBRX It got multiple good news this week but the market sentiment is weighing down the price action! $OCGN Broke few supports but remain in my swing to long strategy. I shared my swing about it my my Live Biotech group! More plans to come! $ALT I have a new prediction and a plan for it for a swing / long this weekend will share with my VIP email group/ Live biotech group! Enjoy your weekend and lets us stay positive! Any questions never hesitate to email me ( all my emails in my profile).
0 · Reply
BeMaWe
BeMaWe Mar. 21 at 3:36 PM
$OCGN
0 · Reply
Latest News on OCGN
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript

Mar 4, 2026, 1:32 PM EST - 17 days ago

Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 8:15 AM EST - 17 days ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Mar 2, 2026, 7:02 AM EST - 19 days ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Feb 9, 2026, 7:02 AM EST - 5 weeks ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 23, 2026, 8:00 AM EST - 2 months ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Jan 21, 2026, 4:37 PM EST - 2 months ago

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 21, 2026, 8:32 AM EST - 2 months ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

Jan 15, 2026, 2:16 PM EST - 2 months ago

Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Jan 15, 2026, 1:15 PM EST - 2 months ago

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 15, 2026, 8:15 AM EST - 2 months ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 13, 2026, 7:00 AM EST - 2 months ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 12, 2026, 6:30 AM EST - 2 months ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Jan 9, 2026, 7:02 AM EST - 2 months ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments

Jan 6, 2026, 12:20 AM EST - 2 months ago

Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 10, 2025, 9:20 AM EST - 3 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 20, 2025, 7:02 AM EST - 4 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:21 PM EST - 4 months ago

Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Nov 5, 2025, 6:30 AM EST - 4 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 5 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Ocugen: A Retinal Disease Juggernaut In The Making

Sep 23, 2025, 11:11 AM EDT - 6 months ago

Ocugen: A Retinal Disease Juggernaut In The Making

Ocugen Shares Are Trading Higher Monday: What's Going On?

Sep 15, 2025, 4:29 PM EDT - 6 months ago

Ocugen Shares Are Trading Higher Monday: What's Going On?

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 15, 2025, 6:03 AM EDT - 6 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Sep 2, 2025, 7:02 AM EDT - 7 months ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 13, 2025, 6:27 AM EDT - 7 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 12, 2025, 3:45 PM EDT - 7 months ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 8 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 12:30 PM EDT - 8 months ago

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Aug 1, 2025, 8:25 AM EDT - 8 months ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 21, 2025, 7:30 AM EDT - 8 months ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 18, 2025, 7:02 AM EDT - 8 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jul 17, 2025, 6:30 AM EDT - 8 months ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 23, 2025, 7:30 AM EDT - 9 months ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Ocugen: Three Potential Gene-Therapy Filings By 2028

Jun 18, 2025, 4:00 PM EDT - 9 months ago

Ocugen: Three Potential Gene-Therapy Filings By 2028

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 16, 2025, 7:02 AM EDT - 9 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

Jun 11, 2025, 7:30 AM EDT - 10 months ago

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Jun 5, 2025, 7:02 AM EDT - 10 months ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025, 7:02 AM EDT - 10 months ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 10:02 AM EDT - 11 months ago

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025, 8:01 AM EDT - 11 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 11 months ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 29, 2025, 7:30 AM EDT - 11 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Apr 8, 2025, 8:02 AM EDT - 1 year ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 10:59 AM EST - 1 year ago

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 27, 2025, 8:46 AM EST - 1 year ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 8:00 AM EST - 1 year ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 12, 2025, 7:42 AM EST - 1 year ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Feb 3, 2025, 6:30 AM EST - 1 year ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 27, 2025, 6:30 AM EST - 1 year ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Martinsucks
Martinsucks Mar. 21 at 10:37 PM
$OCGN horse manure stock.
0 · Reply
James94E
James94E Mar. 21 at 10:13 PM
$OCGN is it Monday yet?.................. ........... What about now?
0 · Reply
simbha
simbha Mar. 21 at 10:05 PM
$OCGN Last 4 weeks markets are at peak and war uncertainty made big players to swing huge on simple expected news and then cash out. I think similar big investors (warrants) played similar game. CEO is happy and so did warrant player. Meanwhile big sharks and MM cashed out on options and added to their long term. Retailers we were as usual emotional excited as well as disappointed. Usual compromise that we will prosper on lon term @$20. Good luck longs..
0 · Reply
Merlintrader
Merlintrader Mar. 21 at 8:43 PM
$OCGN https://www.merlintrader.com/biotech-trading-without-the-fairy-tales-risks-catalysts-and-reality/
0 · Reply
Tradefun1979
Tradefun1979 Mar. 21 at 8:29 PM
$OCGN Not again, this time please!6 years a long time to do a business correctly. Promoters should pay attention and keep this floating. Some are really frustrated like me and very reasonably. But hope will persist for the incoming pr.
0 · Reply
elronjr
elronjr Mar. 21 at 8:00 PM
$OCGN $BTAI $HUMA $BMEA $NOTE I took a beating this week. Note is as per usual garbage and a lost cause at this point. Really hoping earnings reports this week for $BTAI $HUMA $BMEA pull through and actually save me. This is an absolute shitshow. Humacyte probably has the dumbest people running the company. I’m hoping they have something up their sleeve this ER to have that damn stock go above 1-1.5$
1 · Reply
luminouslumens
luminouslumens Mar. 21 at 7:54 PM
$ASST $VTIX $OCGN $IKT $LPTH Some block flow leaders to watch next week!!
0 · Reply
DookieDungaroos
DookieDungaroos Mar. 21 at 4:51 PM
$OCGN
2 · Reply
jacksparo
jacksparo Mar. 21 at 4:01 PM
$SLS Automatic shelf offering but remember everyone here most likely still betting big on what might happen post Regal results announced. The rumors, the exaggeration, the epic optimization all part of some people way of expressing but I am personally go by what the numbers will tell… I will share my update and my plan in a full detailed email this weekend with realistic predictions and remember risk always going to be part of the Biotech Game! $IBRX It got multiple good news this week but the market sentiment is weighing down the price action! $OCGN Broke few supports but remain in my swing to long strategy. I shared my swing about it my my Live Biotech group! More plans to come! $ALT I have a new prediction and a plan for it for a swing / long this weekend will share with my VIP email group/ Live biotech group! Enjoy your weekend and lets us stay positive! Any questions never hesitate to email me ( all my emails in my profile).
0 · Reply
BeMaWe
BeMaWe Mar. 21 at 3:36 PM
$OCGN
0 · Reply
3I_ATLAS
3I_ATLAS Mar. 21 at 3:15 PM
$OCGN MUSTARD😆
1 · Reply
plamendimitrov
plamendimitrov Mar. 21 at 3:07 PM
$OCGN http://archive.fast-edgar.com/20260320/ANB2K22C8W2299Z2222M2ZZZBQKGR2U2N282
1 · Reply
Jessmaster
Jessmaster Mar. 21 at 2:16 PM
$OCGN
0 · Reply
Fox1Fox2
Fox1Fox2 Mar. 21 at 1:31 PM
$OCGN https://www.marketbeat.com/instant-alerts/ocugen-nasdaqocgn-upgraded-by-wall-street-zen-to-hold-rating-2026-03-21/
1 · Reply
dval59
dval59 Mar. 21 at 12:23 PM
$OCGN I'm still in positive territory, so....
3 · Reply
AnchorMB
AnchorMB Mar. 21 at 12:21 PM
$OCGN and ........... . They may still hold the original 20M shares This is the wildcard. If they: • exercised 10M, • still hold 20M common, • still hold 10M unexercised warrants… …then they control 40M potential shares in a stock with ~50M short. That is enormous leverage over the tape. The question becomes: Are they a liquidity provider or a strategic accumulator?
0 · Reply
VINCENZOCOCCOTTI
VINCENZOCOCCOTTI Mar. 21 at 12:09 PM
$OCGN The price action last week was largely defined by the added supply of 10mm shares from warrants conversion being liquidated. The large prints on the tape at the end of trading on Friday signify that the selling was completed and reported. This is bullish in that the the company's financial runway is extended into 2027 and that half of the 20 million warrants, that were serving as short term overhang, have been liquidated. I love that Shankar waited till the end of the week to issue the press release so as not to spook the markets further. Those shares were priced at 1.50, a huge discount to the share price at the beginning of the week. Typically, when traders are aware of a large block "in the hole", the shares free fall to the discount price. This was done in a relatively neat and tidy manner, in my opinion.
1 · Reply
StJude2024
StJude2024 Mar. 21 at 9:40 AM
$OCGN Any Bulls know the reasons why we had such a big pull back the last few days?
2 · Reply
Pit1908
Pit1908 Mar. 21 at 6:39 AM
$OCGN To maintain operations, an institutional investor recently exercised options, bringing in an additional $15 million. Together with a previous capital increase from January, funding is now officially secured until the first quarter of 2027. 🧬🔬💰 This financial cushion is essential to overcome the upcoming clinical hurdles. The timeline for the coming months sets clear operational goals: March 2026: Full Phase 2 data for OCU410 against dry age-related macular degeneration. 🧬 Third quarter of 2026: Planned application for approval of the lead candidate OCU400 and first data on the Stargardt therapy OCU410ST. 🧬 First quarter of 2027: Publication of the final Phase 3 results for OCU400. 🧬
0 · Reply
Tomassso
Tomassso Mar. 21 at 3:54 AM
$OCGN ooo nooo, pumpers, what happened here again? I feel betrayed again
1 · Reply
Madpatsy
Madpatsy Mar. 21 at 2:44 AM
$OCGN Chuck Norris bought OCGN Shares. Just think about that.
1 · Reply
Bk187
Bk187 Mar. 21 at 2:31 AM
$OCGN the majority of the market is red, calm you tits! Been a pretty solid run up. I think there is more green to come imo
0 · Reply